Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the earnings per share (EPS) high or low?
The earnings per share (EPS) of -2.90 is 98% below its 3-year average of -1.47, near the low end of its 3-year range (-2.90–-0.66).
39.76% below its 12-month average of -2.08.
Reported quarterly EPS; no daily interpolation. Q2 FY2026 (2026-06-30): -0.73.
EPS growth vs the same fiscal quarter in the prior fiscal year, last 8 comparable quarters.
EARNINGS PER SHARE (EPS)
-2.90
EARNINGS PER SHARE (EPS) AVG TTM
-2.08
EARNINGS PER SHARE (EPS) AVG 3Y
-1.47
EARNINGS PER SHARE (EPS) AVG 5Y
N/A
EARNINGS PER SHARE (EPS) AVG 10Y
N/A
EARNINGS PER SHARE (EPS) AVG 15Y
N/A
EARNINGS PER SHARE (EPS) AVG 20Y
N/A
CURRENT VS TTM AVG
-39.76%
CURRENT VS 3Y AVG
-97.95%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Upstream Bio, Inc.
Market Cap
$249.79M
Earnings Per Share (EPS)
-2.90
TTM Avg
-2.08
3Y Avg
-1.47
5Y Avg
N/A
Market Cap
$248.50M
Earnings Per Share (EPS)
-2.23
TTM Avg
-2.66
3Y Avg
-2.57
5Y Avg
-2.57
Market Cap
$247.62M
Earnings Per Share (EPS)
-0.43
TTM Avg
-0.62
3Y Avg
-0.66
5Y Avg
-0.59
Market Cap
$247.27M
Earnings Per Share (EPS)
-5.64
TTM Avg
-3.00
3Y Avg
-4.16
5Y Avg
-2.76
Market Cap
$255.88M
Earnings Per Share (EPS)
-0.27
TTM Avg
-2.29
3Y Avg
-2.81
5Y Avg
-2.11
Market Cap
$256.47M
Earnings Per Share (EPS)
-0.54
TTM Avg
-0.72
3Y Avg
-0.78
5Y Avg
-0.86
Market Cap
$241.94M
Earnings Per Share (EPS)
N/A
TTM Avg
-1.09
3Y Avg
-1.28
5Y Avg
-1.70
Market Cap
$241.39M
Earnings Per Share (EPS)
2.79
TTM Avg
-1.35
3Y Avg
-2.70
5Y Avg
-10.73
Market Cap
$241.34M
Earnings Per Share (EPS)
-0.46
TTM Avg
-0.61
3Y Avg
-0.71
5Y Avg
-1.81
| NAME | MARKET CAP | EARNINGS PER SHARE (EPS) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Upstream Bio, Inc. (UPB) | $249.79M | -2.90 | -2.08 | -1.47 | N/A |
| CAMP4 Therapeutics Corporation (CAMP)vs › | $248.50M | -2.23 | -2.66 | -2.57 | -2.57 |
| Galectin Therapeutics Inc. (GALT)vs › | $247.62M | -0.43 | -0.62 | -0.66 | -0.59 |
| Sol-Gel Technologies Ltd. (SLGL)vs › | $247.27M | -5.64 | -3.00 | -4.16 | -2.76 |
| Anika Therapeutics, Inc. (ANIK)vs › | $255.88M | -0.27 | -2.29 | -2.81 | -2.11 |
| AC Immune S.A. (ACIU)vs › | $256.47M | -0.54 | -0.72 | -0.78 | -0.86 |
| Lifecore Biomedical, Inc. (LFCR)vs › | $241.94M | N/A | -1.09 | -1.28 | -1.70 |
| Q32 Bio Inc. (QTTB)vs › | $241.39M | 2.79 | -1.35 | -2.70 | -10.73 |
| Quantum-Si incorporated (QSI)vs › | $241.34M | -0.46 | -0.61 | -0.71 | -1.81 |
| Palisade Bio, Inc. (PALI)vs › | $258.63M | -0.53 | -5.25 | -13.51 | -397.38 |
Trailing EPS (TTM)
$-2.90
Forward EPS (Est.)
$-2.87
P/E Ratio
N/A
Formula: EPS = Net Income / Weighted Average Shares Outstanding
Why EPS matters:
EPS (Earnings Per Share) represents the portion of a company's profit allocated to each outstanding share. Higher EPS indicates greater profitability on a per-share basis.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EARNINGS PER SHARE (EPS) |
|---|---|
| 2025-12-31 | -2.66 |
| 2024-12-31 | -1.49 |
| 2023-12-31 | -1.05 |
| 2022-12-31 | -0.66 |
